COMPANY PROFILE // THE 014 REPORT
Niagen Bioscience, Inc.
NAGE (Nasdaq) · Formerly: ChromaDex Corp.; CODY RESOURCES, INC.
Assembled from 2 government sources in 0.1 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2024-12-16 (last 24 months).
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record.
Niagen Bioscience, Inc. is an SEC-registered operating company in medicinal chemicals & botanical products, incorporated in DE, based in Los Angeles, CA; listed as NAGE (Nasdaq).[source] It reported revenue of $129.4 million for the fiscal year ended 2025-12-31.[source] It has filed 34 documents with the SEC in the last 12 months; the latest is Form 10-Q, filed 2026-11-04.[source] Its largest institutional holders on 13F filings are BlackRock, Inc., SteelPeak Wealth, LLC, VANGUARD CAPITAL MANAGEMENT LLC (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 8-K Item 4.01 filed.[source]
- red0
- amber1
- info0
- BlackRock, Inc.$13.3M
- SteelPeak Wealth, LLC$11.2M
- VANGUARD CAPITAL MANAGEMENT LLC$6.8M
- Qube Research & Technologies Ltd$5.2M
- GEODE CAPITAL MANAGEMENT, LLC$4.7M
- UBS Group AG$4.1M
- GOLDMAN SACHS GROUP INC$4.0M
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$3.7M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Fried Robert N · Chief Executive Officer (Director,Officer) · latest Form 4 2026-02-24 · filing · LinkedIn search
- Lopez Carlos Luis · SVP, General Counsel (Officer) · latest Form 4 2026-02-24 · filing · LinkedIn search
- Pamir Ozan · Chief Financial Officer (Officer) · latest Form 4 2026-02-24 · filing · LinkedIn search
- Cohen Ann · Director · latest Form 4 2025-06-25 · filing · LinkedIn search
- Jaksch Frank L Jr · Director · latest Form 4 2025-06-25 · filing · LinkedIn search
- Ng Wang Yu Gary · Director · latest Form 4 2025-06-25 · filing · LinkedIn search
- Patrick Kristin · Director · latest Form 4 2025-06-26 · filing · LinkedIn search
- Rubin Steven D · Director · latest Form 4 2025-06-25 · filing · LinkedIn search
- Shahbazi Hamed · Director · latest Form 4 2025-07-03 · filing · LinkedIn search
- YU Wing Tak Wendy · Director · latest Form 4 2025-06-26 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Proskauer Rose LLP · Exhibit 5.1 legal opinion, S-3 filed 2026-06-29
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001386570 | source |
| EIN | 26-2940963 | source |
| California SOS entitypossible match | 0003356344-0001-1 | record |
| Business address (SEC) | 10900 WILSHIRE BLVD, LOS ANGELES, CA, 90024 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-01 · in 101 days · Next 10-K due (period ended 2026-12-31; Large accelerated filer) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 171 days · Next 10-Q due (period ended 2027-03-31; Large accelerated filer) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2833 (medicinal chemicals & botanical products): 43 companies in our records share this code.
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- USANA HEALTH SCIENCES INC · 103 SEC filings in 12 months
- Definium Therapeutics, Inc. · 98 SEC filings in 12 months
- Curaleaf Holdings, Inc. · 75 SEC filings in 12 months
- MARIMED INC. · 73 SEC filings in 12 months
- AURORA CANNABIS INC · 63 SEC filings in 12 months
- Canopy Growth Corp · 63 SEC filings in 12 months · 3 flags
- Trulieve Cannabis Corp. · 63 SEC filings in 12 months · 1 flag
- Cronos Group Inc. · 54 SEC filings in 12 months
- Tilray Brands, Inc. · 51 SEC filings in 12 months · 1 flag
- IM Cannabis Corp. · 51 SEC filings in 12 months
- Jushi Holdings Inc. · 47 SEC filings in 12 months
- MediWound Ltd. · 46 SEC filings in 12 months
ADDRESS · ZIP CODE
Location context
At the same address (2)
- WASSERMAN FOUNDATION · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Super League Enterprise, Inc. · Patrick Kristin
- Laird Superfood, Inc. · Patrick Kristin
- OPKO HEALTH, INC. · Rubin Steven D
- Cocrystal Pharma, Inc. · Rubin Steven D
- Entera Bio Ltd. · Rubin Steven D
- Red Violet, Inc. · Rubin Steven D
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-04 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-08-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-04 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-07-10 filing 424B5 · SEC EDGAR
- 2026-07-09 filing EFFECT · SEC EDGAR
- 2026-06-29 filing 8-K items 5.07 · SEC EDGAR
- 2026-06-29 filing S-3 · SEC EDGAR
- 2026-05-06 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-05-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-29 filing ARS · SEC EDGAR
- 2026-04-29 filing DEFA14A · SEC EDGAR
- 2026-04-29 filing Proxy statement · SEC EDGAR
- 2026-03-19 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-03-04 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-03-04 filing Annual report (10-K) · SEC EDGAR
- 2026-02-26 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-02-24 insider First Form 3/4/5 on record for Lopez Carlos Luis (SVP, General Counsel) · SEC Forms 3/4/5
- 2025-12-22 filing 8-K items 1.01,7.01,9.01 · SEC EDGAR
- 2025-11-17 insider First Form 3/4/5 on record for Pamir Ozan (Chief Financial Officer) · SEC Forms 3/4/5
- 2025-11-06 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2025-11-04 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2025-11-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-10-06 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2025-08-08 filing S-8 · SEC EDGAR
- 2025-08-08 filing S-8 · SEC EDGAR
- 2025-08-06 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2025-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-07-29 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2025-07-03 insider First Form 3/4/5 on record for Shahbazi Hamed (Director) · SEC Forms 3/4/5
170 earlier entries
- 2025-06-27 officer change 8-K items 5.02,5.07,9.01
- 2025-06-26 insider First Form 3/4/5 on record for Patrick Kristin (Director)
- 2025-06-26 insider First Form 3/4/5 on record for YU Wing Tak Wendy (Director)
- 2025-06-25 insider First Form 3/4/5 on record for Cohen Ann (Director)
- 2025-06-25 insider First Form 3/4/5 on record for Jaksch Frank L Jr (Director)
- 2025-06-25 insider First Form 3/4/5 on record for Ng Wang Yu Gary (Director)
- 2025-06-25 insider First Form 3/4/5 on record for Rubin Steven D (Director)
- 2025-05-07 filing 8-K items 2.02,7.01,9.01
- 2025-05-07 filing Quarterly report (10-Q)
- 2025-04-29 filing ARS
- 2025-04-29 filing DEFA14A
- 2025-04-29 filing Proxy statement
- 2025-04-09 insider First Form 3/4/5 on record for Fried Robert N (Chief Executive Officer)
- 2025-03-19 filing 8-K items 5.03,7.01,9.01
- 2025-03-10 name change Name changed from ChromaDex Corp.
- 2025-03-04 filing 8-K items 2.02,7.01,9.01
- 2025-03-04 filing Annual report (10-K)
- 2025-02-27 officer change 8-K items 5.02
- 2024-12-16 filing 8-K items 4.01
- 2024-12-13 filing 144
- 2024-12-04 filing 8-K items 8.01
- 2024-11-21 filing 424B3
- 2024-11-21 filing 8-K items 1.01,9.01
- 2024-10-31 filing 8-K items 2.02,7.01,9.01
- 2024-10-31 filing Quarterly report (10-Q)
- 2024-10-11 filing 8-K items 4.01,9.01
- 2024-09-20 officer change 8-K items 5.02,9.01
- 2024-08-23 filing 144
- 2024-08-21 filing SC 13D/A
- 2024-08-21 filing SC 13D/A
- 2024-08-07 filing 8-K items 2.02,7.01,9.01
- 2024-08-07 filing Quarterly report (10-Q)
- 2024-07-16 officer change 8-K items 5.02
- 2024-06-25 officer change 8-K items 5.02,9.01
- 2024-06-24 filing 8-K items 5.07
- 2024-05-08 filing 8-K items 2.02,7.01,9.01
- 2024-05-08 filing Quarterly report (10-Q)
- 2024-04-25 filing ARS
- 2024-04-25 filing DEFA14A
- 2024-04-25 filing Proxy statement
- 2024-03-06 filing 8-K items 2.02,7.01,9.01
- 2024-03-06 filing Annual report (10-K)
- 2023-12-13 filing 8-K items 1.01,2.03,9.01
- 2023-11-08 filing 8-K items 2.02,7.01,9.01
- 2023-11-08 filing Quarterly report (10-Q)
- 2023-09-07 filing SC 13D/A
- 2023-08-09 filing 8-K items 2.02,7.01,9.01
- 2023-08-09 filing Quarterly report (10-Q)
- 2023-07-06 filing 424B5
- 2023-07-05 filing EFFECT
- 2023-06-30 filing CORRESP
- 2023-06-27 filing UPLOAD
- 2023-06-22 filing S-8
- 2023-06-22 filing S-3
- 2023-06-20 officer change 8-K items 5.02,5.07,9.01
- 2023-05-10 filing 8-K items 2.02,7.01,9.01
- 2023-05-10 filing Quarterly report (10-Q)
- 2023-04-28 filing ARS
- 2023-04-28 filing DEFA14A
- 2023-04-28 filing Proxy statement
- 2023-04-19 filing PRE 14A
- 2023-03-17 filing 8-K items 5.03,9.01
- 2023-03-08 filing 8-K items 2.02,7.01,9.01
- 2023-03-08 filing Annual report (10-K)
- 2023-01-05 officer change 8-K items 5.02,9.01
- 2022-11-17 filing 424B3
- 2022-11-16 filing EFFECT
- 2022-11-14 filing CORRESP
- 2022-11-09 filing UPLOAD
- 2022-11-03 filing S-3
- 2022-11-02 filing Quarterly report (10-Q)
- 2022-11-02 filing 8-K items 2.02,7.01,9.01
- 2022-10-14 filing D
- 2022-10-11 filing 424B5
- 2022-10-11 filing 8-K items 1.01,7.01,8.01,9.01
- 2022-10-03 filing SC 13D/A
- 2022-10-03 filing SC 13D/A
- 2022-10-03 filing 8-K items 1.01,1.02,9.01
- 2022-09-07 filing CT ORDER
- 2022-08-10 filing Quarterly report (10-Q)
- 2022-08-10 officer change 8-K items 2.02,5.02,7.01,9.01
- 2022-06-21 filing 8-K items 5.07,8.01
- 2022-06-09 officer change 8-K items 5.02
- 2022-05-20 filing SC 13D/A
- 2022-05-20 filing SC 13D/A
- 2022-05-19 filing 8-K items 1.01,7.01,9.01
- 2022-05-12 filing 8-K items 2.02,7.01,9.01
- 2022-05-12 filing Quarterly report (10-Q)
- 2022-04-27 filing DEFA14A
- 2022-04-27 filing Proxy statement
- 2022-04-18 officer change 8-K items 5.02
- 2022-04-15 officer change 8-K items 5.02
- 2022-04-11 officer change 8-K items 5.02
- 2022-04-08 officer change 8-K items 5.02
- 2022-03-23 filing 8-K items 7.01,9.01
- 2022-03-14 filing Annual report (10-K)
- 2022-03-09 filing 8-K items 2.02,7.01,9.01
- 2021-12-15 filing 8-K items 1.01,2.03,9.01
- 2021-12-13 officer change 8-K items 5.02
- 2021-12-01 officer change 8-K items 5.02
- 2021-11-03 filing 8-K items 2.02,7.01,9.01
- 2021-11-03 filing Quarterly report (10-Q)
- 2021-10-29 officer change 8-K items 5.02
- 2021-09-30 filing 8-K items 8.01
- 2021-09-21 filing SC 13D/A
- 2021-09-20 filing SC 13D/A
- 2021-09-17 filing SC 13D/A
- 2021-09-15 filing 8-K items 8.01
- 2021-08-03 filing Quarterly report (10-Q)
- 2021-08-03 filing 8-K items 2.02,7.01,9.01
- 2021-06-22 filing 8-K items 5.07
- 2021-05-06 filing 8-K items 2.02,7.01,9.01
- 2021-05-06 filing Quarterly report (10-Q)
- 2021-04-22 filing EFFECT
- 2021-04-22 filing 424B3
- 2021-04-21 filing CORRESP
- 2021-04-21 filing DEFA14A
- 2021-04-21 filing Proxy statement
- 2021-03-25 filing UPLOAD
- 2021-03-23 filing S-3
- 2021-03-12 filing Annual report (10-K)
- 2021-03-10 filing 8-K items 2.02,7.01,9.01
- 2021-03-03 filing D
- 2021-03-02 filing SC 13D/A
- 2021-02-25 filing 8-K items 3.02
- 2021-02-22 filing 8-K items 1.01,9.01
- 2020-12-09 filing 8-K items 7.01,9.01
- 2020-11-23 filing 8-K items 8.01
- 2020-11-04 filing Quarterly report (10-Q)
- 2020-11-04 filing 8-K items 2.02,7.01,9.01
- 2020-10-28 filing CT ORDER
- 2020-09-11 filing CT ORDER
- 2020-08-18 filing S-8
- 2020-08-17 filing CT ORDER
- 2020-08-06 filing Quarterly report (10-Q)
- 2020-08-06 filing 8-K items 2.02,7.01,9.01
- 2020-07-08 filing 8-K items 8.01
- 2020-06-26 filing EFFECT
- 2020-06-26 filing 424B5
- 2020-06-24 filing CORRESP
- 2020-06-22 officer change 8-K items 5.02,5.07,9.01
- 2020-06-18 filing UPLOAD
- 2020-06-12 filing S-3
- 2020-06-03 filing 424B3
- 2020-06-01 filing EFFECT
- 2020-05-29 filing 8-K items 7.01,9.01
- 2020-05-28 filing UPLOAD
- 2020-05-28 filing CORRESP
- 2020-05-26 filing CT ORDER
- 2020-05-21 filing S-3
- 2020-05-20 filing D
- 2020-05-18 filing 10-K/A
- 2020-05-18 filing Quarterly report (10-Q)
- 2020-05-12 filing NT 10-Q
- 2020-05-11 filing 8-K items 2.02,7.01,9.01
- 2020-05-07 filing 8-K items 3.02
- 2020-04-29 filing SC 13D/A
- 2020-04-29 filing 8-K items 1.01,9.01
- 2020-04-21 filing DEFA14A
- 2020-04-21 filing Proxy statement
- 2020-04-02 filing CT ORDER
- 2020-03-24 filing CT ORDER
- 2020-03-24 filing CT ORDER
- 2020-03-19 filing CT ORDER
- 2020-03-10 filing 8-K items 2.02,7.01,9.01
- 2020-03-10 filing Annual report (10-K)
- 2020-01-10 officer change 8-K items 5.02
- 2019-11-12 filing 8-K items 2.02,7.01,9.01
- 2019-11-12 filing 8-K items 1.01,2.03
- 2019-11-12 filing Quarterly report (10-Q)
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-04 (within 30 days) 10-Q filed
- 2026-11-04 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-04 (older) 10-Q filed
- 2026-08-04 (older) 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-10 (older) 424B5 filed (PROSPECTUS SUPPLEMENT)
- 2026-07-09 (older) EFFECT filed
- 2026-06-29 (older) 8-K filed: Item 5.07 shareholder vote
- 2026-06-29 (older) S-3 filed (REGISTRATION STATEMENT)
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:NAGE The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
4 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1386570 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | NAGE / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 262940963 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001386570 | SEC EDGAR / IRS |
| CUSIP | 171077407 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001386570 | SEC EDGAR |
possible match: matched by name only, not merged (2)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110070663837 (CHROMADEX INC) | name-exact:contested: name equals 'Chromadex' but other unrelated entities share it | EPA ECHO facilities |
| EPA FRS id | 110072042881 (CHROMADEX INC) | name-exact:contested: name equals 'Chromadex' but other unrelated entities share it | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $129,423,000 | 2025-12-31 | 10-K, XBRL Revenues | as filed | 2026-11-20 06:10 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | $17,382,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 06:10 UTC | Report an error |
| Total assets (at 2025-12-31) | $106,406,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 06:10 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $76,533,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 06:10 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $64,788,000 | 2025-12-31 | 10-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | as filed | 2026-11-20 06:10 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-04 | SEC EDGAR company profile | as filed | 2026-11-20 06:10 UTC | Report an error |
| SIC industry | 2833 Medicinal Chemicals & Botanical Products | 2026-11-04 | SEC EDGAR company profile | as filed | 2026-11-20 06:10 UTC | Report an error |
| State of incorporation | DE | 2026-11-04 | SEC EDGAR company profile | as filed | 2026-11-20 06:10 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-04 | SEC EDGAR company profile | as filed | 2026-11-20 06:10 UTC | Report an error |
| Business address | 10900 WILSHIRE BLVD, SUITE 600, LOS ANGELES, CA, 90024 | 2026-11-04 | SEC EDGAR company profile | as filed | 2026-11-20 06:10 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-04 | SEC EDGAR company profile | as filed | 2026-11-20 06:10 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $13,504,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 06:10 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $2,817,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 06:10 UTC | Report an error |
| Form D total offering amount (D filed 2022-10-14) | $3,100,000 | 2022-10-14 | D | as filed | 2026-11-20 06:10 UTC | Report an error |
| Form D total amount sold (D filed 2022-10-14) | $3,100,000 | 2022-10-14 | D | as filed | 2026-11-20 06:10 UTC | Report an error |
| Form D industry group | Biotechnology | 2022-10-14 | D | as filed | 2026-11-20 06:10 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2022-10-14 | D | as filed | 2026-11-20 06:10 UTC | Report an error |
| Form D date of first sale | 2022-09-30 | 2022-10-14 | D | as filed | 2026-11-20 06:10 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001386570-26-000056
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $27,192,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001386570-26-000056 | 2026-11-20 06:10 UTC | Report an error |
| Net income (loss) | -$1,173,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001386570-26-000056 | 2026-11-20 06:10 UTC | Report an error |
| Cash and cash equivalents | $69,509,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001386570-26-000056 | 2026-11-20 06:10 UTC | Report an error |
| Contract liabilities, noncurrent | $2,162,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001386570-26-000056 | 2026-11-20 06:10 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-04 Filing 10-Q filed
- 2026-11-04 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-04 Filing 10-Q filed
- 2026-08-04 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-10 Filing 424B5 filed (PROSPECTUS SUPPLEMENT)
- 2026-07-09 Filing EFFECT filed
- 2026-06-29 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-06-29 Filing S-3 filed (REGISTRATION STATEMENT)
- 2026-05-06 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-06 Filing 10-Q filed
- 2026-04-29 Filing ARS filed
- 2026-04-29 Filing DEFA14A filed
- 2026-04-29 Filing DEF 14A filed
- 2026-03-19 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-03-04 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-03-04 Filing 10-K filed
- 2026-02-26 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2025-12-22 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-11-06 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2025-11-04 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-11-04 Filing 10-Q filed
- 2025-10-06 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-08-08 Filing S-8 filed (REGISTRATION STATEMENT)
- 2025-08-08 Filing S-8 filed (REGISTRATION STATEMENT)
- 2025-08-06 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-11-04 8-K Item 2.02, Results of Operations and Financial Condition
On November 4, 2026, Niagen Bioscience, Inc. (the “Company”) issued a press release announcing its earnings for the quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such… the 8-K · retrieved 2026-11-20 06:10 UTC - 2026-11-04 8-K Item 7.01, Regulation FD Disclosure
On November 4, 2026, the Company released a corporate presentation which it made available on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.2. The information in this Item 7.01 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. the 8-K · retrieved 2026-11-20 06:10 UTC - 2026-08-04 8-K Item 2.02, Results of Operations and Financial Condition
On August 4, 2026, Niagen Bioscience, Inc. (the “Company”) issued a press release announcing its earnings for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing. the 8-K · retrieved 2026-11-20 06:10 UTC - 2026-08-04 8-K Item 7.01, Regulation FD Disclosure
On August 4, 2026, the Company released a corporate presentation which it made available on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.2. The information in this Item 7.01 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. the 8-K · retrieved 2026-11-20 06:10 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCHROMADEX INC · name equals 'Chromadex' but other unrelated entities share it · sx:epa:110070663837 Compare
- possible matchCHROMADEX INC · name equals 'Chromadex' but other unrelated entities share it · sx:epa:110072042881 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | $13,349,063 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:10 UTC | Report an error |
| 2 | SteelPeak Wealth, LLC | $11,165,412 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:10 UTC | Report an error |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | $6,848,987 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:10 UTC | Report an error |
| 4 | Qube Research & Technologies Ltd | $5,183,801 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:10 UTC | Report an error |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | $4,717,806 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:10 UTC | Report an error |
| 6 | UBS Group AG | $4,093,714 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:10 UTC | Report an error |
| 7 | GOLDMAN SACHS GROUP INC | $4,028,150 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:10 UTC | Report an error |
| 8 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3,736,176 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:10 UTC | Report an error |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | $3,720,283 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:10 UTC | Report an error |
| 10 | STATE STREET CORP | $3,453,979 | 2026-06-30 | SEC 13F filing | 2026-11-20 06:10 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
California business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCHROMADEX, INC · name equals 'Chromadex' but other unrelated entities share it · sx:cabiz:la:0003356344-0001-1 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchChromaDex, Inc. · name equals 'Chromadex' but other unrelated entities share it · sx:ctgov:h76752040c550c3a4 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1386570.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001386570. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.